These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12143913)

  • 1. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.
    Sheehan DV; Burnham DB; Iyengar MK; Perera P;
    J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL; Lipschitz A; Pitts CD; Davies JT
    Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
    Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
    J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
    Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
    J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea.
    Higuchi T; Hong JP; Jung HY; Watanabe Y; Kunitomi T; Kamijima K
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):655-63. PubMed ID: 21895859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS; Soares CN; Yonkers KA; Bellew KM; Bridges IM; Steiner M
    Psychosom Med; 2004; 66(5):707-13. PubMed ID: 15385695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.
    Roy-Byrne PP; Perera P; Pitts CD; Christi JA
    J Clin Psychiatry; 2005 Oct; 66(10):1228-33. PubMed ID: 16259535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
    Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
    J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.